EOS Education

The educational modules in this section are designed to provide a foundational understanding of eosinophilic inflammation and diseases in which eosinophils play a key pathological role.

Click on the topics below to get started

EOS Inflammation

Eosinophils activate inflammatory cells, causing tissue damage and contributing to the pathophysiology of a range of diseases.^1–9 This module provides an introduction to eosinophils and an overview of how they may drive disease pathology.

Learn more

SEA

Most patients with severe asthma have an eosinophilic phenotype, and eosinophils have been found to play central roles in driving pathological functions such as airway remodelling and mucus plugging.^10–13 This module provides an introduction to the role of eosinophils in severe asthma pathology, and how this converts to clinical outcomes.

Learn more

EGPA

EGPA is a rare disease characterized by systemic eosinophilic inflammation and vasculitis damaging multiple systems in the body.^14–19 This module provides an introduction to the role of eosinophils in EGPA, and how this links to the complex, multisystemic nature of the disease.^17–21

Learn more

HES

HES is a heterogeneous group of rare, often idiopathic disorders, defined by persistently high eosinophil levels (≥1500 cells/mm³) in the blood and tissues.^22–24 Patients can have widespread organ damage, with diverse symptoms affecting the skin, lungs, and several other systems.^25,26 This module provides an overview of how eosinophils mediate organ damage and dysfunction in HES.^23,27

For additional information on HES, alongside other diseases, you can visit AZMedicalScience.com

Learn more

EGPA, eosinophilic granulomatosis and polyangiitis; EOS, eosinophil; HES, hypereosinophilic syndrome; SEA, severe eosinophilic asthma.

Patterson MF, et al. J Asthma Allergy 2015;8:125–134
Lambrecht BN, Hammad H. Nat Immunol 2015;16:45–56
Trivedi SG, Lloyd CM. Cell Mol Life Sci 2007;64:1269–1289
Denburg JA, Keith PK. Chest 2008;134:1037–1043
Rosenberg HF, et al. Nat Rev Immunol 2013;13:9–22
Gandhi NA, et al. Nat Rev Drug Discov 2016;15:35–50
AbuJabal R, et al. Clin Exp Allergy 2024;54:538–549
Jacobsen EA, et al. Annu Rev Immunol 2021;39:719–757
Quirce S, et al. Front Immunol 2023;14:1192284
Heaney LG, et al. Chest 2021;160:814–830
Siddiqui S, et al. J Allergy Clin Immunol 2023;152:841–857
Hussain M, Liu G. Cells 2024;13:384
Dunican EM, et al. J Clin Invest 2018;128:997–1009
Jennette JC, et al. Arthritis Rheum 2013;65:1–11
Furuta S, et al. Allergol Int 2019;68:430–436
Khoury P, et al. Nat Rev Rheumatol 2014;10:474–483
Chakraborty RK, Aeddula NR. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Treasure Island, FL, USA: StatPearls Publishing, 2024
Gioffredi A, et al. Front Immunol 2014;5:549
Doubelt I, et al. ACR Open Rheumatol 2021;3:404–412
Trivioli G, et al. Rheumatology 2020;59:iii84–iii94
Fagni F, et al. Front Med (Lausanne) 2021;8:627776
Chen MM, et al. J Allergy Clin Immunol Pr 2022;10:1217-1228.e3
Valent P, et al. Allergy 2023;78:47–59
Klion AD. Blood 2015;126:1069–1077
Ogbogu PU, et al. J Allergy Clin Immunol 2009;124:1319-1325.e3
Hwee J, et al. Ann Allergy Asthma Immunol 2023;130:768–775
Groh M, et al. Orphanet J Rare Dis 2023;18:100

Veeva ID: Z4-82627
Date of preparation: June 2026

Are you a healthcare professional?

EOS Education

EOS Inflammation

SEA

EGPA

HES

Abbreviations & references